Pages that link to "Q34994511"
Jump to navigation
Jump to search
The following pages link to Intradermal Vaccinations With RNA Coding for TAA Generate CD8 and CD4 Immune Responses and Induce Clinical Benefit in Vaccinated Patients (Q34994511):
Displaying 50 items.
- mRNA-Based Therapeutics - Advances and Perspectives (Q26741950) (← links)
- Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination (Q26769044) (← links)
- Immunity to Pathogens Taught by Specialized Human Dendritic Cell Subsets (Q26777195) (← links)
- Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond (Q26861563) (← links)
- Vaccines for the 21st century (Q27007529) (← links)
- Immunotherapy in gastric cancer (Q27010472) (← links)
- Intradermal electroporation of naked replicon RNA elicits strong immune responses (Q27310340) (← links)
- Whole blood cells loaded with messenger RNA as an anti-tumor vaccine. (Q33740816) (← links)
- Generation of more effective cancer vaccines (Q34169981) (← links)
- Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response (Q34494018) (← links)
- Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma (Q34870799) (← links)
- The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function (Q35652459) (← links)
- Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study (Q35746834) (← links)
- Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one. (Q35886889) (← links)
- Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin (Q35939486) (← links)
- Nonviral delivery of self-amplifying RNA vaccines (Q36221799) (← links)
- Biomaterials for mRNA delivery (Q36271488) (← links)
- Developing mRNA-vaccine technologies (Q36684597) (← links)
- Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals (Q36757051) (← links)
- Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy (Q37012691) (← links)
- Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose (Q37126611) (← links)
- Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals (Q37612455) (← links)
- Induction of Protective Immunity against Toxoplasma gondii in Mice by Nucleoside Triphosphate Hydrolase-II (NTPase-II) Self-amplifying RNA Vaccine Encapsulated in Lipid Nanoparticle (LNP). (Q37737615) (← links)
- mRNA vaccination as a safe approach for specific protection from type I allergy. (Q37965722) (← links)
- RNA-based vaccines (Q38006567) (← links)
- MUC1 immunotherapy is here to stay (Q38045428) (← links)
- mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic. (Q38071900) (← links)
- RNA pulsed dendritic cells: an approach for cancer immunotherapy (Q38073077) (← links)
- MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge (Q38091088) (← links)
- Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise. (Q38113267) (← links)
- Cancer vaccination by electro-gene-transfer. (Q38143182) (← links)
- HLA ligandome tumor antigen discovery for personalized vaccine approach (Q38148779) (← links)
- Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines (Q38199151) (← links)
- A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs (Q38206520) (← links)
- Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy (Q38217593) (← links)
- mRNA-based therapeutics--developing a new class of drugs (Q38252360) (← links)
- The ReNAissanCe of mRNA-based cancer therapy (Q38255012) (← links)
- mRNA transcript therapy (Q38264088) (← links)
- Antigen-specific vaccines for cancer treatment (Q38284692) (← links)
- Electroporation-enhanced delivery of nucleic acid vaccines (Q38285418) (← links)
- Lipid-based mRNA vaccine delivery systems (Q38300777) (← links)
- A novel delivery platform based on Bacteriophage MS2 virus-like particles (Q38863707) (← links)
- Update on Mucin-1 immunotherapy in cancer: a clinical perspective (Q38603410) (← links)
- New challenges in therapeutic vaccines against HIV infection. (Q38692205) (← links)
- Vectors and strategies for nonviral cancer gene therapy (Q38694798) (← links)
- Vaccines for established cancer: overcoming the challenges posed by immune evasion (Q38769021) (← links)
- HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy (Q38839148) (← links)
- RNA Vaccination Therapy: Advances in an Emerging Field (Q38891036) (← links)
- Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses (Q38964752) (← links)
- Modified mRNA as a therapeutic tool to induce cardiac regeneration in ischemic heart disease (Q39027005) (← links)